| Pair Name | Bufalin, 1,25-dihydroxyvitamin D3 | ||
| Phytochemical Name | Bufalin (PubChem CID: 9547215 ) | ||
| Anticancer drug Name | 1,25-dihydroxyvitamin D3 (PubChem CID: 5280453 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Bufalin, 1,25-dihydroxyvitamin D3 | |||
| Disease Info | [ICD-11: 2A60.Z] | Acute myeloid leukemia | Investigative | |
| Gene Regulation | Up-regulation | Expression | CYP24A1 | hsa1591 |
| Up-regulation | Expression | VDR | hsa7421 | |
| In Vitro Model | HL-60 | Adult acute myeloid leukemia | Homo sapiens (Human) | CVCL_0002 |
| Result | The Na(+),K(+)-ATPase inhibitor bufalin modulates VDR function through several mechanisms, including Erk MAP kinase activation and increased nuclear VDR expression. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. J Steroid Biochem Mol Biol. 2009 Apr;114(3-5):144-51. doi: 10.1016/j.jsbmb.2009.01.022. | Click |
